Core Viewpoint - The company, a leader in China's third-party SPD solutions market, is preparing for an IPO on the Hong Kong Stock Exchange, aiming to leverage its market position and growth potential in the healthcare sector [1][4]. Company Overview - The company submitted its IPO application to the Hong Kong Stock Exchange on January 21, 2025, with Haitong International as the sole sponsor [1]. - It is the largest third-party SPD solution provider in China, holding a market share of 29.2% as of 2024 [1][10]. - The company's SPD solutions include software systems, smart hardware, and professional services, aimed at improving procurement, storage, distribution, and usage management of medical supplies [1]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 3.78 billion and a net profit of RMB 0.58 billion [5]. - In the first nine months of 2025, the company achieved revenues of RMB 3.06 billion, reflecting a year-on-year growth of 21.59%, and a net profit of RMB 0.43 billion, up by 7.66% [1][5]. - The gross profit margin for the first nine months of 2025 was approximately 38.79%, while the net profit margin was around 14.14% [5]. Market Dynamics - The overall market size for SPD solutions in China is projected to grow from RMB 184 billion in 2019 to RMB 1,815 billion by 2024, with a compound annual growth rate (CAGR) of 58.1% [8]. - The market is expected to reach RMB 10,574 billion by 2029, with a CAGR of 42.3% from 2024 to 2029 [8]. Deployment and Reach - As of September 30, 2025, the company's SPD solutions were deployed in 116 hospitals across 13 provinces in China, including 3 out of 8 A++ hospitals and 61 out of 91 tertiary hospitals [3]. - The company has achieved significant market penetration in economically developed regions, such as the Yangtze River Delta, with 82 hospitals utilizing its SPD solutions in that area [3]. Competitive Landscape - The company is compared with peers such as Jianhui Information and Saili Medical, which have also undergone IPOs, highlighting its competitive positioning in the market [11].

Company Overview - Guoyi Technology has submitted an application for listing on the Hong Kong Stock Exchange, with Haitong International Capital as its sole sponsor. The company is a leader in the third-party SPD solution market in China, holding a market share of 29.2% as of 2024 [1][3]. - The company primarily generates revenue through SPD solutions and in-hospital IDS solutions, with SPD solutions accounting for 98.2% and 98.5% of revenue in 2024 and the first three quarters of 2025, respectively [3][4]. Financial Performance - The company reported significant revenue growth, with revenues of 378 million yuan and 306 million yuan for 2024 and the first nine months of 2025, representing year-on-year growth of 52.4% and 21.9% [2]. - Net profit showed volatility, with figures of 50 million yuan and 32 million yuan for the same periods, reflecting a year-on-year increase of 994% and a decrease of 16.7%, respectively [2]. - As of November 2025, the company had cash and cash equivalents of 184 million yuan [2]. Market Dynamics - The healthcare market in China is expanding, with total healthcare expenditure projected to reach 9.76 trillion yuan in 2024, driven by an aging population [1]. - The SPD solution market is expected to grow significantly, with a projected compound annual growth rate (CAGR) of 58.1% from 2024 to 2029, reaching a market size of 1,057.4 billion yuan by 2029 [8]. Competitive Landscape - Guoyi Technology is the first third-party SPD solution provider in China and has established a strong market presence, with a significant lead over its competitors [8]. - The third-party SPD solution market is highly concentrated, with the top five players holding approximately 51.7% of the market share [8]. Customer Base and Growth Potential - The company serves a diverse range of hospitals, with 116 hospitals as clients by the first three quarters of 2025, including 91 tertiary hospitals, which account for 78.4% of its client base [5]. - The penetration rate of SPD solutions in tertiary hospitals was approximately 36.1% in 2024, expected to reach 90% by 2029, indicating substantial growth opportunities [10]. Profitability and Cost Management - The company has maintained a positive trend in gross margin, with figures of 37.1%, 41.8%, and 38.8% from 2023 to the first three quarters of 2025 [6]. - The management expense ratio improved by 2.59 percentage points to 10.34% in the first three quarters of 2025, indicating effective cost management [6]. Investment Sentiment - Early investors have seen significant returns, with valuations increasing substantially across multiple funding rounds, although the latest round saw a modest increase [10]. - The company has attracted diverse capital from various investors, indicating strong market interest and confidence in its growth potential [10].

Core Viewpoint - The company, Guoyi Technology, is preparing for an IPO on the Hong Kong Stock Exchange, focusing on its SPD (Supply Chain Process Design) solutions, which are crucial for optimizing hospital supply chains in a rapidly aging population and expanding healthcare market in China [1][10]. Company Overview - Guoyi Technology was established in 2016 and has developed SPD solutions in collaboration with major hospitals, expanding its market presence to various provinces [2][10]. - The company holds a 29.2% market share in China's third-party SPD solutions, making it the largest provider in this sector [1][7]. Financial Performance - Revenue for the first nine months of 2024 and 2025 was reported at 3.78 billion RMB and 3.06 billion RMB, reflecting year-on-year growth of 52.4% and 21.9% respectively [2]. - The net profit for the same periods was 0.5 billion RMB and 0.32 billion RMB, with significant fluctuations, showing a 994% increase in 2024 followed by a 16.7% decrease in 2025 [2]. - The company reported a cash and cash equivalents balance of 1.84 billion RMB as of November 2025 [2]. Revenue Sources - The primary revenue source is the SPD solutions, which accounted for 98.2% and 98.5% of total revenue in 2024 and 2025 respectively [2][3]. - The IDS (In-Hospital Intelligent Delivery System) solutions were introduced in 2024 but have not yet achieved significant commercial success [2][5]. Market Potential - The SPD solutions market in China is projected to grow from 181.5 billion RMB in 2024 to 1,057.4 billion RMB by 2029, with a compound annual growth rate (CAGR) of 42.3% [7]. - The penetration rate of SPD solutions in tertiary hospitals is expected to rise from 36.1% in 2024 to 90% by 2029, indicating substantial growth opportunities [9]. Client Base - As of the first three quarters of 2025, Guoyi Technology served 116 hospitals, with 91 being tertiary hospitals, representing 78.4% of its client base [4][9]. - The company has a low client concentration, with the top five clients contributing only 25% of total revenue [4]. Profitability and Costs - The gross margin has shown an upward trend, with figures of 37.1%, 41.8%, and 38.8% from 2023 to the first three quarters of 2025 [5][6]. - The company has optimized its expense ratios, with a notable decrease in management expense ratio by 2.59 percentage points to 10.34% in 2025 [5][6]. Investment Landscape - Guoyi Technology has attracted significant investment, with its valuation increasing substantially across multiple funding rounds, indicating strong investor confidence [10]. - The company’s latest post-investment valuation reached 1.914 billion RMB, reflecting a 33.8 times increase since the angel round [10].